Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment

被引:184
作者
Croci, Diego O.
Zacarias Fluck, Mariano F.
Rico, Maria J.
Matar, Pablo
Rabinovich, Gabriel A. [1 ]
Graciela Scharovsky, O.
机构
[1] Consejo Nacl Invest Cient & Tecn, IBYME, Inst Expt Biol & Med, RA-1033 Buenos Aires, DF, Argentina
[2] Univ Nacl Rosario, Sch Med Sci, Inst Expt Genet, RA-2000 Rosario, Argentina
[3] Univ Buenos Aires, Dept Biol Chem, FCEyN, Buenos Aires, DF, Argentina
关键词
inflammation; immunosuppression; tumor-immune escape; tumor immunoediting;
D O I
10.1007/s00262-007-0343-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Accumulating evidence indicates that a dynamic cross-talk between tumors and the immune system can regulate tumor growth and metastasis. Increased understanding of the biochemical nature of tumor antigens and the molecular mechanisms responsible for innate and adaptive immune cell activation has revolutionized the fields of tumor immunology and immunotherapy. Both the protective effects of the immune system against tumor cells (immunosurveillance) and the evasion of tumor cells from immune attack (tumor-immune escape) have led to the concept of cancer immunoediting, a proposal which infers that a bidirectional interaction between tumor and inflammatory/regulatory cells is ultimately responsible for orchestrating the immunosuppressive network at the tumor site. In this context, a major challenge is the potentiation or redirection of tumor antigen-specific immune responses. The success in reaching this goal is highly dependent on an improved understanding of the interactions and mechanisms operating during the different phases of the cancer immunoediting process. In this review, we discuss the multiple defense and counterattack strategies that tumors have devised in order to evade immune attack and to thwart the effectiveness of several immunotherapeutic approaches.
引用
收藏
页码:1687 / 1700
页数:14
相关论文
共 148 条
[1]   The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape [J].
Algarra, I ;
García-Lora, A ;
Cabrera, T ;
Ruiz-Cabello, F ;
Garrido, F .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) :904-910
[2]  
André S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO
[3]  
2-W
[4]   Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[5]   Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy [J].
Bai, Xue-Feng ;
Liu, Jin-Qing ;
Joshi, Pramod S. ;
Wang, Lizhong ;
Yin, Lijie ;
Labanowska, Jadwiga ;
Heerema, Nyla ;
Zheng, Pan ;
Liu, Yang .
CANCER RESEARCH, 2006, 66 (16) :8241-8249
[6]   CHARACTERIZATION OF THE ANTITUMOR IMMUNE-RESPONSE IN HUMAN CANCERS AND STRATEGIES FOR IMMUNOTHERAPY [J].
BAXEVANIS, CN ;
PAPAMICHAIL, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1994, 16 (03) :157-179
[7]   Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway [J].
Bird, CH ;
Sutton, VR ;
Sun, JR ;
Hirst, CE ;
Novak, A ;
Kumar, S ;
Trapani, JA ;
Bird, PI .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) :6387-6398
[8]   GM2 expression in renal cell carcinoma: Potential role in tumor-induced T-cell dysfunction [J].
Biswas, Kaushik ;
Richmond, Amy ;
Rayman, Patricia ;
Biswas, Soumika ;
Thornton, Mark ;
Sa, Gaurisankar ;
Das, Tanya ;
Zhang, Renliang ;
Chahlavi, Ali ;
Tannenbaum, Charles S. ;
Novick, Andrew ;
Bukowski, Ronald ;
Finke, James H. .
CANCER RESEARCH, 2006, 66 (13) :6816-6825
[9]   Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro [J].
Blank, C ;
Kuball, J ;
Voelkl, S ;
Wiendl, H ;
Becker, B ;
Walter, B ;
Majdic, O ;
Gajewski, TF ;
Theobald, M ;
Andreesen, R ;
Mackensen, A .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) :317-327
[10]   METABOLISM OF TRYPTOPHAN .2. METABOLISM OF TRYPTOPHAN IN PATIENTS SUFFERING FROM CANCER OF THE BLADDER [J].
BOYLAND, E ;
WILLIAMS, DC .
BIOCHEMICAL JOURNAL, 1956, 64 (03) :578-582